Bayer AG: Elinzanetant Shows Promise In Treating Menopause-Associated Vasomotor Symptoms In Phase 3 Clinical Trials
Elinzanetant reduced the frequency and severity of menopause-associated vasomotor symptoms in two phase 3 clinical trials. Elinzanetant was safe and ...